Back to Journals » OncoTargets and Therapy » Volume 10

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report

Authors Deng L, Wang Y, Lu W, Liu Q, Wu J, Jin J

Received 3 November 2016

Accepted for publication 5 February 2017

Published 13 March 2017 Volume 2017:10 Pages 1521—1525

DOI https://doi.org/10.2147/OTT.S126471

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Jianmin Xu

Linghui Deng, Yue Wang, Wenbin Lu, Qian Liu, Jie Wu, Jianhua Jin

Department of Oncology, Wujin People’s Hospital, Affiliated to Jiangsu University, Changzhou, People’s Republic of China

Abstract: Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for patients with ovarian cancer. Here, we present the case of a 50-year-old Chinese woman with advanced ovarian cancer, who received apatinib at a daily dose of 500 mg for 28 days per cycle after failure of fourth-line chemotherapy. Favorable oncologic outcome was achieved in this case after treatment with apatinib. The patient’s progression-free survival is now 11.3 months, and she is taking apatinib and capecitabine as maintenance treatment. The common side effect of apatinib was fatigue; however, the toxicity of apatinib was controllable and tolerable. Thus, apatinib may be an option for chemotherapy-refractory advanced epithelial ovarian cancer, but this still warrants further investigation.

Keywords:
advanced epithelial ovarian cancer, apatinib, chemotherapy, angiogenesis inhibitor, targeted therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]